Postprandial glucose regulation and diabetic complications

Archives of Internal Medicine

Volumn 164, Issue 19, 2004, Pages 2090-2095

  Ceriello, Antonio ^a   Hanefeld, Markolf ^b   Leiter, Lawrence ^c   Monnier, Louis ^d   Moses, Alan ^e   Owens, David ^f   Tajima, Naoko ^g   Tuomilehto, Jaakko ^h  

^a UNIVERSITY OF UDINE   (Italy)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d LAPEYRONIE HOSPITAL   (France)

^e JOSLIN DIABETES CENTER   (United States)

^f LLANDOUGH HOSPITAL   (United Kingdom)

^g JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; PLACEBO;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEART ARREST; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HORMONAL REGULATION; HUMAN; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; POSTPRANDIAL STATE; PREDICTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVASCULARIZATION; REVIEW; STROKE; VASCULAR DISEASE;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; POSTPRANDIAL PERIOD;

EID: 6944252200     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.164.19.2090     Document Type: Review

References (58)

1. Kannel WB, McGee DL. Diabetes and cardiovascular diseases: the Framingham Study. JAMA. 1979;241:2035-2038.
2. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998;21:518-524.
3. DECODE Study Group. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? reanalysis of European epidemiological data. BMJ. 1998;317:371-375.
4. Qiao Q, Nakagami T, Tuomilehto J, et al; International Diabetes Epidemiology Group; DECODA Study Group. Comparison of the fasting and the 2-h glucose criteria for diabetes indifferent Asian cohorts. Diabetologia. 2000;43:1470-1475.
5. Qiao Q, Tuohilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia. 2003;46(suppl 1):M17-M21.
6. Bonora E, Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia. 2001;44:2107-2114.
7. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46(suppl 1):M9-M16.
8. Avignon A, Radauceanu A, Monnier L. Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822-1826.
9. American Diabetes Association. Postprandial blood glucose. Diabetes Care. 2001;24:775-778.
10. Lindholm E, Agardh E, Tuomi T, Groop L, Agardh CD. Classifying diabetes according to the new WHO clinical stages. Eur J Epidemiol. 2001;17:983-989.
11. Wolever TMS, Chiasson JL, Csima A, et al. Variation of postprandial plasma glucose, payability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care. 1998;21:336-340.
12. Pyorala K, Savolainen E, Lehtovirta E, Punsar S, Siltanen P. Glucose tolerance and coronary heart disease: Helsinki Policemen Study. J Chronic Dis. 1979;32:729-745.
13. Donahue RP, Abbott RD, Reed DM, Yano K. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry: Honolulu Heart Program. Diabetes. 1987;36:689-692.
14. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care. 1998;21:360-373.
15. Jackson CA, Yudkin JS, Forrest RD. A comparison of the relationships of the glucose tolerance test and the glycated hemoglobin assay with diabetic vascular disease in the community: the Islington Diabetes Survey. Diabetes Res Clin Pract. 1992;17:111-123.
16. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia. 1999;42:926-931.
17. Meigs JB, Nathan DM, D'Agostino RB Sr, Wilson PW. Fasting and post-challenge glycemiaand cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care. 2002;25:1845-1850.
18. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycemia confirmed as a risk factor for mortality. Diabetologia. 1999;42:1050-1054.
19. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study. Diabetes Care. 1998;21:1236-1239.
20. DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617-621.
21. Hanefeld M, Fischer S, Julius U, et al; DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
22. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23(suppl 2):B21-B29.
23. Chiasson J, Josse RG, Gomis R, Hanefeld M, Karasik A, Laasko M; STOP-NIDDM Trial Research Group. Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: the STOP-NIDDM Trial. JAMA. 2003;290:486-494.
24. Taskinen MR, Lahdenpera S, Syvanne M. New insights into lipid metabolism in non-insulin-dependent diabetes mellitus. Ann Med. 1996;28:335-340.
25. Keefe F, de Faire U, Mercuzi M, et al. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men. Atherosclerosis. 1998;141:307-314.
26. Cavallero E, Dachet C, Neufcou D, Wirquin E, Mathe D, Jacotot B. Postprandial amplification of lipo-protein abnormalities in controlled type II diabetic subjects: relationship to postprandial lipemia and C-peptide/glucagon levels. Metabolism. 1994;43:270-278.
27. Heine RJ, Dekker JM. Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia. 2002;45:461-475.
28. De Caterina R. Endothelial dysfunctions: common denominators in vascular disease. Curr Opin Lipidol. 2000;11:9-23.
29. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211-1218.
30. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820.
31. Pecoraro RE, Chen MS, Porte D Jr. Glycosylated hemoglobin and fasting plasma glucose in the assessment of outpatient glycemic control in NIDDM. Diabetes Care. 1982;5:592-599.
32. 1c in the Diabetes Control and Complications Trial. Diabetes Care. 2002;25:275-278.
33. 1c interrelationship in type 2 diabetes: implications for treatment and monitoring of metabolic control. Diabetes Care. 2001;24:2023-2029.
34. Reaven GM, Hollembeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes. 1988;37:1020-1024.
35. Riddle MC. Evening insulin strategy. Diabetes Care. 1990;13:676-686.
36. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients. Diabetes Care. 2003;26:881-885.
37. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med. 1994;121:928-935.
38. Wolffenbuttel BH, Landgraf R; on behalf of the Dutch and German Repaglinide Study Group. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care. 1999;22:463-467.
39. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care. 1999;22:789-794.
40. Doyle ME, Egan JM. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev. 2003;55:105-131.
41. Phillips LS, Dunning BE. Nateglinide (Starlix): update on a new antidiabetic agent. Int J Clin Pract. 2003;57:535-541.
42. Owens DR, Luzio SD, Ismail I, Bayer T. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. Diabetes Care. 2000;23:518-523.
43. Saad M, Hale P, Khutoryansky N. Efficacy of repaglinide vs nateglinide: as monotherapy or metformin combination therapy [abstract]. Diabetes. 2002;51(suppl 2):A133.
44. Stumvoll M, Haring H-U. Glitazones: clinical effects and molecular mechanisms. Ann Med. 2002;34:217-222.
45. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997;100:530-537.
46. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491-497.
47. 1c. Diabetes Care. 2000;23:1236-1241.
48. Home PD, Lindholm A, Hylleberg B, Round P; for the UK Insulin Aspart Study Group. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998;21:1904-1909.
49. WHO. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications, Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1999.
50. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2004;27(supp (1):S15-S35.
51. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8:5-11.
52. Alberti KGMM, Gries FA. Management of non-insulin-dependent diabetes mellitus in Europe: a consensus view. Diabet Med. 1988;5:275-281.
53. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and managementof diabetes in Canada. Can J Diabetes Care. 2003;23:56-69.
54. Buse JB. Should postprandial glucose be routinely measured and treated to a particular target? no! Diabetes Care. 2003;26:1615-1618.
55. Diabetes Control and Complications Trials (DCCT) Research Group. The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trials. Diabetes. 1996;45:1289-1298.
56. Stratton IM, Adler Al, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
57. Egger M, Davey Smith G, Stettler C, Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet Med. 1997;14:919-928.
58. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation. 2004;110:214-219.